Fate Therapeutics, Inc. (FATE)
2.11
+0.02
(+0.96%)
USD |
NASDAQ |
Oct 23, 16:00
2.11
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Enterprise Value : 168.13M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 168.13M |
| October 22, 2026 | 165.80M |
| October 21, 2026 | 163.46M |
| October 20, 2026 | 162.30M |
| October 19, 2026 | 138.96M |
| October 16, 2026 | 130.79M |
| October 15, 2026 | 146.54M |
| October 14, 2026 | 148.29M |
| October 13, 2026 | 155.30M |
| October 12, 2026 | 170.47M |
| October 09, 2026 | 176.30M |
| October 08, 2026 | 170.47M |
| October 07, 2026 | 172.80M |
| October 06, 2026 | 189.14M |
| October 05, 2026 | 205.47M |
| October 02, 2026 | 192.64M |
| October 01, 2026 | 190.30M |
| September 30, 2026 | 198.47M |
| September 29, 2026 | 199.64M |
| September 28, 2026 | 199.64M |
| September 25, 2026 | 196.14M |
| September 24, 2026 | 193.81M |
| September 23, 2026 | 205.47M |
| September 22, 2026 | 222.98M |
| September 21, 2026 | 217.14M |
| Date | Value |
|---|---|
| September 18, 2026 | 217.14M |
| September 17, 2026 | 215.98M |
| September 16, 2026 | 206.64M |
| September 15, 2026 | 196.14M |
| September 14, 2026 | 194.97M |
| September 11, 2026 | 191.47M |
| September 10, 2026 | 193.81M |
| September 09, 2026 | 206.64M |
| September 08, 2026 | 213.64M |
| September 04, 2026 | 211.31M |
| September 03, 2026 | 204.31M |
| September 02, 2026 | 207.81M |
| September 01, 2026 | 205.47M |
| August 31, 2026 | 200.81M |
| August 28, 2026 | 205.47M |
| August 27, 2026 | 218.31M |
| August 26, 2026 | 221.81M |
| August 25, 2026 | 219.48M |
| August 24, 2026 | 206.64M |
| August 21, 2026 | 193.81M |
| August 20, 2026 | 207.81M |
| August 19, 2026 | 231.15M |
| August 18, 2026 | 220.64M |
| August 17, 2026 | 227.65M |
| August 14, 2026 | 221.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 534.42M |
| Amgen, Inc. | 280.78B |
| Anika Therapeutics, Inc. | 273.50M |
| BioCryst Pharmaceuticals, Inc. | 2.436B |
| Imunon, Inc. | 6.743M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.16M |
| Revenue (Quarterly) | 2.082M |
| Total Expenses (Quarterly) | 32.24M |
| EPS Diluted (Quarterly) | -0.2505 |
| Gross Profit Margin (Quarterly) | -33.53% |
| Profit Margin (Quarterly) | -1.45K% |
| Earnings Yield | -49.91% |
| Normalized Earnings Yield | -49.73 |